Esophageal squamous cell carcinoma (ESCC), the dominant subtype of esophageal cancer, is one of the most common digestive tumors worldwide. In this study, we confirmed that HOXC13, a member of the homeobox HOXC gene family, was significantly upregulated in ESCC and its overexpression was associated with poorer clinical characteristics and worse prognosis. Moreover, knockdown of HOXC13 inhibited proliferation and induced apoptosis of ESCC through upregulating CASP3.
seeking new functional genes and biomarkers in ESCC development may yield alternative approaches for managing esophageal cancer.
As known, HOX genes are a group of related genes containing a well-conserved DNA sequence called the homeobox. 4 The protein products of HOX genes function as transcription factors that bind to specific nucleotide sequences on the DNA called enhancers where they either activate or repress genes. 5 As a member of the homeobox HOXC gene family, HOXC13 correlates with the development of hair, nail and filiform papilla. [6] [7] [8] It has been reported that HOXC13 is highly expressed in ameloblastoma, 9 odontogenic tumors, 10 metastatic melanoma 11 and liposarcoma; 12 moreover, knockdown of HOXC13 inhibited cell growth, and resulted in cell cycle arrest, in colon cancer. 13 However, the expression and biological function of HOXC13 in ESCC have not been investigated. In this study, we confirmed that HOXC13 could play an oncogenic role in ESCC through repressing transcription of CASP3.
MicroRNA (miRNA) are a class of small non-coding RNA molecules that regulate gene expression at post-transcriptional level.
14 They bind to the 3 0 untranslated regions (3 0 UTR) of target genes, and regulate the translation and degradation of target mRNA. 15 MicroRNA play important roles in multiple physiological processes, including developmental timing, cell death and proliferation, hematopoiesis, and progression of many kinds of human cancers. [16] [17] [18] [19] Plenty of miRNA have been reported to be related to tumor proliferation and patient survival in ESCC. [20] [21] [22] [23] Technologies aimed at replacing tumor suppressor miRNA that are lost during cancer progression have emerged as promising cancer therapies. 24 Herein, we
show that miR-503 targets the 3 0 UTR of HOXC13 and represses proliferation of ESCC. Further study of the role of miR-503-HOXC13-CASP3 axis in ESCC initiation and development is expected to provide new biomarkers and therapeutic targets for ESCC.
| MATERIALS AND METHODS

| Data sources and bioinformatics
The TCGA dataset, named TCGA_ESCA_exp_HiSeq-2015-02-24, was downloaded from the UCSC Cancer Browser (https://genomecancer.ucsc.edu/). 25 All normalized gene expression values can be obtained from "genomicMatrix" files. Using the co-expression tool in cBioPortal (http://www.cbioportal.org/), 26 we obtained a list of 120 genes (Table S1) found that expression of HOXC13 is significantly higher in esophageal carcinoma tissues than in para-tumor tissues ( Figure 1A ). Figure 1B ). In addition, F I G U R E 2 Knockdown of HOXC13 inhibits proliferation of esophageal squamous cell carcinoma (ESCC) cells and induces apoptosis. A,B, Two specific shRNA (sh1 and sh2) of HOXC13 were designed and synthesized, and the transfection efficiency in ECA109 and TE13 cells was measured by quantitative RT-PCR and western blot. C, Cell Counting Kit-8 assays revealed that knockdown of HOXC13 inhibited proliferation of ECA109 cells (sh1, P < .0001; sh2, P < .0001) and TE13 cells (sh1, P < .0001; sh2, P < .0001). D, XCELLigence System assays also showed that knockdown of HOXC13 inhibited proliferation of ECA109 cells (sh1, P < .0001; sh2, P < .0001) and TE13 cells (sh1, P < .0001; sh2, P < .0001). E, Colony formation ability was inhibited by knockdown of HOXC13 in ECA109 cells (sh1, P = .0002; sh2, P = .0001) and TE13 cells (sh1, P = .0036; sh2, P = .0037). F, Knockdown of HOXC13 induced apoptosis of ECA109 cells (sh1, P = .0040; sh2, P = .0151) and TE13 cells (sh1, P = .0031; sh2, P = .0026) LUO ET AL.
| Statistical analysis
| 321 F I G U R E 3 HOXC13 induces apoptosis of esophageal squamous cell carcinoma (ESCC) cells through regulating CASP3. A, Gene ontology pathway analysis showed that genes co-expressed with HOXC13 were enriched in the "transcription," "apoptotic process" and "proliferation" pathway. B,C, Quantitative RT-PCR and western blot indicated that expression of CASP3 was significantly upregulated by knockdown of HOXC13. D,E, Z-DEVD-FMK, a specific caspase-3 inhibitor, partially reversed the inhibitory effect of sh-HOXC13 on the proliferation of ECA109 cells. F, Z-DEVD-FMK partially reversed shRNA-HOXC13-induced apoptosis. G, Western blot showed that Z-DEVD-FMK decreased the expression of CASP3 and upregulated PARP, the enzyme digestion substrate of caspase-3 correlation analysis between HOXC13 expression and clinical characteristics indicated that expression of HOXC13 is closely linked to primary tumor stage (P = .010528) and TNM stage (P = .031380) ( Table 1) . By measuring the mRNA expression of HOXC13 in ESCC tissues from patients at the Nanjing Jinling Hospital, we found that HOXC13 was upregulated in 86.7% of 60 ESCC tissues ( Figure 1C ), and overexpression of HOXC13 was associated with greater T stage (P = .0338), N stage (P = .0003) and TNM stage (P = .0062) (Figure 1D ). 
| Knockdown of HOXC13 inhibits esophageal squamous cell carcinoma proliferation and induces apoptosis in vitro
| HOXC13 promotes esophageal squamous cell carcinoma proliferation through influencing CASP3
To explore how HOXC13 exerts its oncogenic activity, a list of the 120 genes that had the highest correlation values with HOXC13
were selected from TCGA esophageal carcinoma dataset. Gene ontology pathway analysis showed that genes co-expressed with | 323 HOXC13 were enriched in the "transcription," "apoptotic process"
and "proliferation" pathway ( Figure 3A) . As HOXC13 might play a pivotal role in apoptosis, we sought to investigate the influence of Therefore, investigating molecules that play important roles in the initiation and progression of ESCC not only helps to elucidate its pathogenic mechanism but also might provide novel molecular markers and therapeutic targets for the diagnosis and treatment of ESCC.
HOXC13, a member of the homeobox HOXC gene family, has been reported to be overexpressed in human liposarcomas, 12 squamous cell carcinoma, 30 skin tumors 31 and prostate cancer. 32 As a transcription factor, HOXC13 synergistically regulates the expression of Zfp521, which has been identified as a B-cell proto-oncogene causing leukemia. 33 Recent studies show that BMI-1, which is a regulator of HOXC13, and is overexpressed in breast and other cancers, promotes self-renewal of cancer stem-like cells; 34 knockdown of BMI-1 causes cell-cycle arrest, and derepresses p16INK4a in HeLa cells. 35 Moreover, knockdown of HOXC13 affected cell growth, and resulted in cell cycle arrest, in colon cancer. 13 In accordance with these studies, we have uncovered an oncogenic role for HOXC13 in ESCC, by regulation of apoptosis, especially by influencing CASP3.
Apoptosis is a process of programmed cell death that occurs in multicellular organisms and inhibition of apoptosis can result in a number of cancers. [36] [37] [38] Apoptosis is generally characterized by phosphatidylserine externalization, depolarization of mitochondrial membrane, caspase-3 activation and DNA fragmentation. 39, 40 As one of the most important executioners in the apoptotic process, caspase-3 contains a cysteine residue (Cys-163) and a histidine residue In conclusion, our study showed that HOXC13 expression was significantly elevated in ESCC, and correlated with worse clinical characteristics and poorer prognosis. HOXC13 promoted proliferation and inhibited apoptosis through repressing transcription of CASP3. Moreover, miR-503 was able to inhibit ESCC proliferation by suppressing the expression of HOXC13.
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